-
ESMO 2022: Summary of Recent Advances in Lung Cancer, Targeted Immunotherapy
Time of Update: 2022-10-02
Preliminary analysis of the Phase III ADAURA study showed that adjuvant oshitinib therapy significantly improved disease-free survival (DFS) in patients with complete excision of EGFR-sensitive mutations (ex19del/L858R) compared with placebo.
-
Focal nodular hyperplasia of the liver (FNH)
Time of Update: 2022-10-02
Male, 21Y, outpatient, medical history unknownImage performance: CT pan scanning and normal liver tissue show equal density, uniform density, rapid and obvious uniform strengthening of arterial lesions, small flake low-density shadow (scarring) in the center, portal phase and delayed phase contrast agent rapid withdrawal is equal density, central low-density shadow delayed strengthening.
-
Research frontiers of ADC connectors
Time of Update: 2022-10-02
In the case of a random cysteine-bound anti-Her2 ADC, Val-Ala showed less aggregation in a high DAR structure compared to Val-Cit. On the other hand, the two hyenons exhibit similar buffering stability, histoproteinase B release efficiency, cell viability, and histopathological characteristics.
-
Cancer Cell: The team of Shen Hongbing and Hu Zhibin of Southern Medical University reveals a new genetic mechanism of lung cancer pathogenic variation
Time of Update: 2022-10-02
Lung cancer is the malignant tumor with the highest incidence and mortality rate in Chinese. Non-small cell lung cancer accounts for 85% of all lung cancer cases and poses a great threat to the health
-
【Cell】 Shi Hubing/Jingjing team of West China Hospital revealed the drug resistance mechanism of triple-negative breast cancer to MEK inhibitors
Time of Update: 2022-10-02
On September 12, a team led by Professor Shi Hubing of the State Key Laboratory of Biotherapy at West China Hospital of Sichuan University and Professor Jing Jing of West China Hospital of Sichuan University published an article entitled "PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in" in Cell Reports Medicine triple-negative breast cancer" research paper.
-
The Lancet: A study of more than 400,000 Chinese patients shows that type 2 diabetes is indeed related to the risk of "cancer king"! The younger you get, the greater the risk!
Time of Update: 2022-10-02
Patients with T2DM who have been diagnosed for more than 5 years and have elevated FBG levels have an increased risk of pancreatic cancer.
Patients with T2DM who have been diagnosed for more than 5 years and have elevated FBG levels have an increased risk of pancreatic cancer.
-
Science: How do hungry cancer cells convert "food" sources when breaking down protein for energy?
Time of Update: 2022-10-02
In the new study, to better understand the molecular pathways of nutrient conversion in cancer, the research team established screening conditions under which cell growth can ingest monomeric amino acids, or be supported by the megacellular drinking action of extracellular proteins and lysosomal catabolism.
-
The Voice of Silence Lights Up the World: A Surgical Look at the Progress of ESMO Esophageal Cancer Research in 2022
Time of Update: 2022-10-01
This year's ESMO conference announced four studies of immunocombined chemotherapy for neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma, three of which were studies led by Chinese researchers in combination with different chemotherapy regimens of the PD-1 immune checkpoint inhibitor Camrelizumab, including different chemotherapy regimensA single-center, single-arm study enrolled 28 patients (cT1b-cT2 N+ or cT3-cT4aNany) using a two-course regimen of carirelizumab combined with albumin paclitaxel and nidaplatin, with a pCR rate of 41.
-
【The Lancet】A study of more than 400,000 people in China: diabetes is indeed related to the risk of pancreatic cancer! Young people are more dangerous!
Time of Update: 2022-10-01
The study calculated the incidence of pancreatic cancer in patients with new-onset type 2 diabetes (T2DM) and assessed the relationship between pancreatic cancer risk and the age of onset and duration of diabetes.
-
2022 ESMO Prof. Wen Xia: Oral SED's research explores current twists and turns, but it is still worth looking forward to
Time of Update: 2022-10-01
[4]The Phase II AMEERA-3 study was designed to evaluate the efficacy and safety of Amcenestrant monotherapy compared with physician-selected monotherapy (TPC), including fluvixan, aromatase inhibitors, or tamoxifen, in patients with ER+/HER2-localized advanced or metastatic breast cancer who had previously undergone endocrine therapy.
-
Breast cancer cells "chaotic" metastasis, how to choose staging and treatment?
Time of Update: 2022-10-01
Recently, a case report published in the BMC sub-journal detailed the clinical, morphological, pathological and immunohistochemical characteristics of a case of breast cancer with contralateral cervical lymph node metastasis, and discussed the treatment method in combination with the current research, which may be inspiring to everyone ~ screenshot of the first page of the studyBasic facts of the casePatient, female, 30 years of age: right breast mass for 5 months, lymphadenopathy in left neck for 5 days.
-
Kong Yuan's team revealed a new pathogenesis of acute graft-versus-host disease after transplantation
Time of Update: 2022-10-01
Acute graft-versus-host disease (aGvHD) is a common complication after allogeneic hematopoietic stem cell transplantation and is one of the important causes of transplant failure. Corticosteroids are
-
2022 ESMO Prof. Liping Liu: The DATA study provides new evidence-based evidence for prolonged assisted endocrine therapy in high-risk populations
Time of Update: 2022-10-01
In 2022, the European Society of Internal Oncology (ESMO) published updated results from the DATA study (abstract number: 133O)[3], providing ideas for adjuvant endocrine therapy strategies for patients with postmenopausal HR-positive early-stage breast cancer.
-
Professor Cai Zhen: The clinical significance of MRD in MM treatment
Time of Update: 2022-10-01
The prognostic value of MRD assessment is substantial1MRD negative prognostic value is higher than CR, which is an effective predictor of PFS benefitA pooled analysis of three PETHEMA/GEM trials for the newly diagnosed multiple myeloma (NDMM)[9] showed that a negative MRD provided a better prognostic outcome than traditional efficacy assessment (Figure 2).
-
"Chinese Female Breast Cancer Prevention Expert Consensus" released!
Time of Update: 2022-10-01
Breast cancer is the malignant tumor with the highest prevalence and case fatality rate in Chinese women, primary prevention is an important part of breast cancer prevention, and the prevention of bre
-
Which tumors have a high chance of recurrence and metastasis? How can cancer patients prevent and respond?
Time of Update: 2022-10-01
(ii)Which tumors have a high chance of recurrence and metastasis?In general, cancer malignancy can be divided into high, medium, low, large malignant tumors are easy to recur after surgery, such as small cell lung cancer, pancreatic cancer, liver cancer, gallbladder cancer, etc.
-
ESMO 2022 Inventory of advances in the treatment of advanced NSCLC with KRAS mutations
Time of Update: 2022-10-01
2 methodThe CodeBreaK 200 study, the first global, open-label phase III trial of KRAS G12C inhibitors, enrolled 345 patients with KRAS G12C mutant NSCLC after previous advances in platinum-containing chemotherapy and immunotherapy between 4 June 2020 and 26 April 2021 and randomized assignments to oral sotorasib (960 mg per day) or intravenous intravenous docetaxel (75 mg/m2 every 3 weeks) 。 The primary endpoint was PFS assessed by the Blinded Independent Central Review (BICR) against RECIST 1.
-
Multiple organs find tumors, how to find the primary lesion?
Time of Update: 2022-10-01
In the process of tumor diagnosis and treatment, if the patient is diagnosed with malignant tumor in the advanced stage, that is, the tumor cells have metastasized to other organs, in this case, it is very important to clarify the primary and metastatic sites of the tumor.
-
Professor Qiu Hong, a strong |: Take precautions, make adequate preparations, and focus on the management of common adverse reactions of targeted therapy for colorectal cancer
Time of Update: 2022-10-01
Professor Xue Junli, | Brilliant: Focus on immunity, talk about "intestine" things, the opportunities and challenges of coloral cancer immunotherapy PP-FR-CN-0989Past Review 1.
Professor Xue Junli, | Brilliant: Focus on immunity, talk about "intestine" things, the opportunities and challenges of coloral cancer immunotherapy PP-FR-CN-0989Past Review 1.
-
【Nature sub-journal】Academician Huang Wei of the Chinese Academy of Sciences and the team of Professor An Zhongfu/Chen Hongmin found that phosphorescence scintillators can help treat deep tumors
Time of Update: 2022-10-01
This article is the original of the translational medicine network, please indicate the source when reprinting Author: SophiaPhotodynamic therapy (PDT), a less invasive clinical cancer treatment strat
